Search This Blog

Tuesday, July 7, 2026

MeiraGTx: up to $400 million funding from Oberland Capital to advance gene therapies

 

MeiraGTx secures up to $400 million funding from Oberland Capital to advance AAV2-hAQP1 and bota-vec gene therapies

  • Funding includes up to $375 million in non-dilutive royalty financing from Oberland Capital.
  • Agreement also provides up to $25 million in equity funding to MeiraGTx.
  • Capital will support development and commercialization of AAV2-hAQP1 and bota-vec gene therapy programs.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)